## David L Porter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9738450/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia. New England Journal of Medicine, 2011, 365, 725-733.	27.0	3,067
2	Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia. New England Journal of Medicine, 2013, 368, 1509-1518.	27.0	3,021
3	Current concepts in the diagnosis and management of cytokine release syndrome. Blood, 2014, 124, 188-195.	1.4	2,080
4	Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine, 2015, 7, 303ra139.	12.4	1,402
5	Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. New England Journal of Medicine, 2017, 377, 2545-2554.	27.0	1,390
6	Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nature Medicine, 2018, 24, 563-571.	30.7	1,150
7	Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discovery, 2016, 6, 664-679.	9.4	811
8	Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature, 2018, 558, 307-312.	27.8	574
9	Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood, 2015, 126, 1033-1040.	1.4	565
10	Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of Clinical Oncology, 2017, 35, 1154-1161.	1.6	495
11	Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood, 2016, 127, 1117-1127.	1.4	381
12	Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature, 2022, 602, 503-509.	27.8	369
13	Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood, 2017, 130, 2317-2325.	1.4	273
14	A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood, 2006, 107, 1325-1331.	1.4	209
15	Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus,) TJ ETQq1 1 methodravate for provention of graft versus best disease with become point call transplantation	0.784314	rgBT /Overlo
-10	with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematology, the, 2019, 6, e132-e143.	4.0	200
16	Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. , 2018, 6, 137.		182
17	Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2020, 38, 415-422.	1.6	162
18	Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology American Society of Hematology Education Program, 2016, 2016, 567-572	2.5	158

DAVID L PORTER

#	Article	IF	CITATIONS
19	Graft-Versus-Tumor Induction With Donor Leukocyte Infusions as Primary Therapy for Patients With Malignancies. Journal of Clinical Oncology, 1999, 17, 1234-1234.	1.6	124
20	Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy. Blood, 2019, 134, 44-58.	1.4	118
21	Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia. Blood, 2018, 132, 556-556.	1.4	106
22	Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2020, 38, 2862-2871.	1.6	102
23	Chimeric Antigen Receptor Therapy for B-cell Malignancies. Journal of Cancer, 2011, 2, 331-332.	2.5	88
24	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplantation, 2019, 54, 1868-1880.	2.4	86
25	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019. 25. e76-e85.	2.0	85
26	Evolution to plasmablastic lymphoma evades CD19â€directed chimeric antigen receptor T cells. British Journal of Haematology, 2015, 171, 205-209.	2.5	83
27	Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. Journal of Allergy and Clinical Immunology, 2020, 146, 940-948.	2.9	78
28	CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. Journal of Clinical Investigation, 2019, 130, 673-685.	8.2	78
29	Improved Survival After Transplantation of More Donor Plasmacytoid Dendritic or NaÃ <sup>-</sup> ve T Cells From Unrelated-Donor Marrow Grafts: Results From BMTCTN 0201. Journal of Clinical Oncology, 2014, 32, 2365-2372.	1.6	77
30	Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse. Biology of Blood and Marrow Transplantation, 2017, 23, 235-246.	2.0	76
31	Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate. Blood, 2018, 132, 298-298.	1.4	73
32	Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis. Blood, 2017, 129, 906-916.	1.4	56
33	Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients. Clinical Infectious Diseases, 2019, 68, 2003-2009.	5.8	54
34	Early Donor Chimerism Levels Predict Relapse and Survival after Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2014, 20, 1758-1766.	2.0	52
35	High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning. Journal of Clinical Oncology, 2015, 33, 2392-2398.	1.6	52
36	CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. Journal of Clinical Investigation, 2021, 131, .	8.2	52

#	Article	IF	CITATIONS
37	Long-Term Survival and Late Effects among One-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2015, 21, 151-158.	2.0	49
38	Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor –T-cell therapy in B-cell non-Hodgkin lymphomas. Cytotherapy, 2018, 20, 1415-1418.	0.7	45
39	BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. Journal of Clinical Investigation, 2021, 131, .	8.2	45
40	A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs. Blood, 2015, 126, 478-485.	1.4	37
41	<scp>CAR</scp> <scp>T</scp> â€eells merge into the fast lane of cancer care. American Journal of Hematology, 2016, 91, 146-150.	4.1	36
42	Donor leukocyte infusions in myeloid malignancies: new strategies. Best Practice and Research in Clinical Haematology, 2006, 19, 737-755.	1.7	34
43	Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract. Bone Marrow Transplantation, 2019, 54, 212-217.	2.4	34
44	Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1961-1967.	2.0	30
45	Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma. Blood, 2016, 128, 974-974.	1.4	28
46	Autologous stem cell transplantation in first complete remission may not extend progressionâ€free survival in patients with peripheral T cell lymphomas. American Journal of Hematology, 2016, 91, 672-676.	4.1	27
47	Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial. Biology of Blood and Marrow Transplantation, 2019, 25, 515-521.	2.0	24
48	Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor Tâ€cell therapy for chronic lymphocytic leukemia. American Journal of Hematology, 2019, 94, S10-S17.	4.1	22
49	Nelarabine, cyclosphosphamide and etoposide for adults with relapsed Tâ€cell acute lymphoblastic leukaemia and lymphoma. British Journal of Haematology, 2016, 174, 332-334.	2.5	21
50	Erythropoietic protoporphyria in an adult with sequential liver and hematopoietic stem cell transplantation: A case report. American Journal of Transplantation, 2018, 18, 745-749.	4.7	20
51	Risk of invasive fungal infections in patients with <scp>highâ€risk MDS</scp> and <scp>AML</scp> receiving hypomethylating agents. American Journal of Hematology, 2020, 95, 792-798.	4.1	20
52	Biomarkers of Response to Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Chronic Lymphocytic Leukemia. Blood, 2016, 128, 57-57.	1.4	18
53	The promise of chimeric antigen receptor T cells ( <scp>CART</scp> s) in leukaemia. British Journal of Haematology, 2017, 177, 13-26.	2.5	17
54	Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients. Blood, 2016, 128, 3222-3222.	1.4	16

DAVID L PORTER

#	Article	IF	CITATIONS
55	Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination. Medical Oncology and Tumor Pharmacotherapy, 1999, 16, 279-288.	1.1	15
56	A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy. Blood, 2019, 134, 4108-4108.	1.4	14
57	T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL. Blood, 2014, 124, 380-380.	1.4	14
58	Advances in CAR T Therapy for Hematologic Malignancies. Pharmacotherapy, 2020, 40, 741-755.	2.6	11
59	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. , 2020, 8, e001235.		11
60	Novel approaches to allogeneic stem cell therapy. Expert Opinion on Biological Therapy, 2001, 1, 3-15.	3.1	10
61	Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL. Blood, 2012, 120, 717-717.	1.4	10
62	R-CHOP or R-HyperCVAD With or Without Autologous Stem Cell Transplantation for Older Patients With Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 92-97.	0.4	9
63	A Phase I Study Using Single Agent Birinapant in Patients with Relapsed Myelodysplastic Syndrome and Acute Myelogenous Leukemia. Blood, 2014, 124, 3758-3758.	1.4	9
64	Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment. American Journal of Hematology, 2016, 91, 453-460.	4.1	7
65	Toward dual hematopoietic stem-cell transplantation and solid-organ transplantation for sickle-cell disease. Blood Advances, 2018, 2, 575-585.	5.2	7
66	Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitadine for Initial Therapy in Adult Acute Myeloid Leukemia. Blood, 2021, 138, 795-795.	1.4	7
67	Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis. Biology of Blood and Marrow Transplantation, 2018, 24, 594-599.	2.0	6
68	Cellular Adoptive Immunotherapy After Autologous and Allogeneic Hematopoietic Stem Cell Transplantation. Cancer Treatment and Research, 2009, 144, 497-537.	0.5	5
69	Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients. Journal of Antimicrobial Chemotherapy, 2015, 70, 2078-2083.	3.0	4
70	Vitamin D deficiency after allogeneic hematopoietic cell transplantation promotes T-cell activation and is inversely associated with an EZH2-ID3 signature. Transplantation and Cellular Therapy, 2021, 28, 18.e1-18.e1.	1.2	4
71	Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells. Blood, 2020, 136, 30-32.	1.4	4
72	Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models. Blood, 2017, 130, 807-807.	1.4	4

DAVID L PORTER

#	Article	IF	CITATIONS
73	Unrelated donors are associated with improved relapseâ€free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity allogeneic stem cell transplantation. American Journal of Hematology, 2016, 91, 883-887.	4.1	3
74	Chronic Lymphocytic Leukemia Cells Impair Mitochondrial Fitness in CD8+ T Cells and Impede CAR T Cell Efficacy. Blood, 2018, 132, 235-235.	1.4	2
75	Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells. Blood, 2021, 138, 166-166.	1.4	2
76	Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma. Future Oncology, 2022, 18, 2415-2431.	2.4	2
77	Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors. Biology of Blood and Marrow Transplantation, 2018, 24, 1203-1208.	2.0	1
78	Immunotherapy with cells (article not eligible for CME credit). Hematology American Society of Hematology Education Program, 2020, 2020, 590-597.	2.5	1
79	Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay. Transplantation and Cellular Therapy, 2021, 27, 431.e1-431.e8.	1.2	1
80	Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing. Blood, 2018, 132, 2134-2134.	1.4	1
81	Incidence and Predictors of Sars-Cov-2 Antibody Responses Following COVID-19 Vaccination in Allogeneic Stem Cell Transplant Recipients. Blood, 2021, 138, 2888-2888.	1.4	1
82	Salvage therapy with basiliximab and etanercept for severe steroidâ€refractory acute graftâ€versusâ€host disease. American Journal of Hematology, 2022, 97, .	4.1	1
83	Initial Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase I Clinical Trial of Systemic C-MYB Antisense Oligodeoxynucleotide in Subjects with Refractory Hematologic Malignancies. Blood, 2008, 112, 4033-4033.	1.4	0
84	Graft-Vs-Lymphoma (GVL) Induction with Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Primary Cutaneous T Cell Lymphomas (CTCL) Blood, 2010, 116, 4574-4574.	1.4	0
85	Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplant. Journal of Oncology Pharmacy Practice, 2022, , 107815522210807.	0.9	0